RadNet (NASDAQ:RDNT) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

RadNet (NASDAQ:RDNT) posted its earnings results on Sunday. The medical research company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.10, FiscalAI reports. The company had revenue of $622.72 million during the quarter, compared to analyst estimates of $610.87 million. RadNet had a negative net margin of 0.66% and a positive return on equity of 2.77%. RadNet’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.31 earnings per share.

RadNet Stock Up 6.8%

RDNT stock opened at $77.28 on Tuesday. The business’s 50-day moving average price is $61.44 and its 200-day moving average price is $61.71. The stock has a market cap of $6.08 billion, a P/E ratio of -429.31 and a beta of 1.36. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.79. RadNet has a twelve month low of $50.82 and a twelve month high of $85.84.

Key Headlines Impacting RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported record second-quarter revenue of $622.7 million, up 25% year over year and above the $610.9 million analyst consensus. Adjusted EBITDA increased 22.7% to a quarterly record of $99.7 million. RadNet Q2 financial results
• Positive Sentiment: Adjusted EPS of $0.29 exceeded the $0.19 consensus estimate, helping drive investor confidence despite being below $0.34 in the year-ago quarter. RadNet Q2 earnings metrics
• Positive Sentiment: Advanced imaging volumes rose 21.2% overall and 9.6% at same centers, with MRI, CT and PET/CT driving a favorable shift toward higher-value procedures.
• Positive Sentiment: Management raised full-year Imaging Center guidance for revenue to $2.37–$2.42 billion, Adjusted EBITDA to $345–$358 million and free cash flow to $115–$125 million. RadNet healthcare update
• Positive Sentiment: Digital Health revenue grew 56.5% to $32.4 million, while annual recurring revenue nearly doubled to $105.5 million. A newly FDA-cleared breast-ultrasound AI solution and new health-system contracts could support future growth.
• Neutral Sentiment: The earnings call highlighted ongoing acquisitions, joint ventures and investments in AI infrastructure as key growth initiatives. Cash was $726.3 million and net debt was 1.8 times Adjusted EBITDA. RadNet Q2 earnings call transcript
• Negative Sentiment: Digital Health Adjusted EBITDA declined 27.2% to $2.5 million because of investments in sales, marketing, customer service and implementation. RadNet also remained unprofitable on a GAAP basis, with a first-half net loss of $25.9 million.
• Negative Sentiment: Recent insider activity showed sales rather than purchases, which may temper enthusiasm at elevated valuation levels.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a research note on Friday. Barclays reduced their price target on RadNet from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 20th. Zacks Research downgraded shares of RadNet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, RadNet has a consensus rating of “Moderate Buy” and a consensus price target of $87.43.

Insider Buying and Selling

In related news, CEO Cornelis Wesdorp sold 4,750 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total value of $276,022.50. Following the completion of the transaction, the chief executive officer owned 69,075 shares of the company’s stock, valued at approximately $4,013,948.25. This represents a 6.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David L. Swartz sold 2,699 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $53.89, for a total value of $145,449.11. Following the completion of the transaction, the director owned 177,013 shares in the company, valued at $9,539,230.57. The trade was a 1.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 5.14% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On RadNet

Several institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP lifted its stake in RadNet by 39.9% in the 4th quarter. RTW Investments LP now owns 3,938,500 shares of the medical research company’s stock worth $281,012,000 after purchasing an additional 1,122,956 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in RadNet by 30.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,699,082 shares of the medical research company’s stock valued at $192,581,000 after buying an additional 627,936 shares in the last quarter. State Street Corp grew its holdings in RadNet by 1.6% during the 4th quarter. State Street Corp now owns 2,579,073 shares of the medical research company’s stock valued at $184,017,000 after buying an additional 41,356 shares in the last quarter. Invesco Ltd. increased its stake in RadNet by 26.4% in the 4th quarter. Invesco Ltd. now owns 1,596,780 shares of the medical research company’s stock worth $113,930,000 after acquiring an additional 333,911 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of RadNet by 1.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,413,734 shares of the medical research company’s stock worth $107,741,000 after acquiring an additional 19,182 shares in the last quarter. Institutional investors own 77.90% of the company’s stock.

RadNet Company Profile

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.